Physician profile
Paige E Johnson
NPI 1366516841
$2,272.25
in general payments reported to CMS, 2019-2025
21 companies · $473 in 2025
The $473 reported for 2025 was more than what 91% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $395 · 2023: $541 · 2024: $295 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.47 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.07 | 2021-2023 | |
| Syndax Pharmaceuticals, INC. | $262.06 | 2025 | Revuforj |
| Glaxosmithkline, LLC. | $226.91 | 2021-2022 | |
| Sobi, INC | $197.68 | 2022-2025 | |
| Y-Mabs Therapeutics, INC. | $176.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $139.28 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.90 | 2023 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2023 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Antares Pharma, INC. | $112.63 | 2022 | |
| Neurocrine Biosciences, INC. | $103.81 | 2025 | |
| Esperion Therapeutics, INC. | $79.20 | 2021 | |
| Organon LLC | $53.21 | 2024 | |
| Seqirus USA INC | $51.35 | 2024 | |
| Genzyme Corporation | $37.60 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $36.07 | 2024-2025 | |
| Uswm, LLC | $28.60 | 2024 | Iwilfin |
| Incyte Corporation | $24.48 | 2025 | Niktimvo |
| Masimo Corporation | $24.22 | 2022 | |
| Pfizer INC. | $17.30 | 2021 | |
| Astellas Pharma US INC | $15.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.